It is very uncertain whether alglucosidase alfa plus albuterol changes adverse events compared with alglucosidase alfa plus placebo (very low certainty).

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
RR 0.67 [0.38, 1.18]
1 study · 13 participants
Very low

Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer

Adverse events · people with non‐transfusion‐dependent β‐thalassaemia

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 104 participants
Very low

Single foetal haemoglobin inducer at any dose or duration vs placebo or usual care

Adverse events · people with non‐transfusion‐dependent β‐thalassaemia

It is very uncertain whether single foetal haemoglobin inducer at any dose or duration changes adverse events compared with usual care or placebo (very low certainty).

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 56 participants
Very low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1014 participants
Very low

Inhaled NO vs placebo

Adverse events · people with SCD

1 finding from 1 review

Inhaled nitric oxide for treating pain crises in people with sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

RGD peptide matrix vs placebo

Adverse events · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.76 [0.5, 1.17]
1 study · 55 participants
Very low

Summary of findings: nitric oxide vs placebo

Adverse events · children (12 or over) and young adults with cystic fibrosis

It is very uncertain whether summary of findings: nitric oxide changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 30 participants
Very low

Summary of findings: β‐carotene vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Vitamin D vs placebo

Adverse events · people with sickle cell disease

Vitamin D showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Vitamin D supplementation for sickle cell disease 2020 · Cochrane Headline outcomes only
RR 3.16 [0.14, 72.84]
1 study · 37 participants
Low

Summary of findings: oral vitamin E supplementation vs placebo or no treatment

Adverse events · adults and children with cystic fibrosis

Summary of findings: oral vitamin E supplementation showed no clear difference in adverse events compared with placebo or no treatment (low certainty).

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
OR 1 [0.13, 7.94]
1 study · 38 participants
Low

Summary of findings: oral β‐carotene vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings: inhaled antioxidants vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 223 participants
Low